Information  X 
Enter a valid email address

LiDCO Group Plc (LID)

  Print      Mail a friend       Annual reports

Wednesday 16 May, 2018

LiDCO Group Plc

Capital Markets Day & US progress update

RNS Number : 1984O
LiDCO Group Plc
16 May 2018

LiDCO Group Plc

("LiDCO" or the "Company")


Capital Markets Day & US progress update

Two new US HUP contract wins


LiDCO (AIM: LID), the hemodynamic monitoring company, is hosting a Capital Markets Day for investors today at its HQ London 16 Orsman Road, London, N1 5QJ. The presentations will be available later today on the Company's website Except as set out below, no new material price sensitive information will be provided.


Ahead of the Capital Markets Day today LiDCO provides the following update on US progress. The Company has had further success contracting two additional customers to its recently launched differentiated High Usage Programme (HUP) business model. HUP is building momentum after its launch in July 2017, and to date the Company now has four significant US customers.


The two latest customers to sign multi-year contracts are a Level 1 trauma centre in New York and a 1000+ bed hospital in the Mid-West. Whilst the initial orders are for eight monitors in total, the Company expects this to grow significantly as the two hospitals fully recognise the benefits of its technology and the unlimited use programme. Both of these customers have the scope to become substantial contracts over their term. This brings the total number of HUP monitors in the US to 66 units.


If you haven't already registered and would like to attend today please register with Walbrook PR on the number below or email [email protected] 


Commenting on the US progress, Matt Sassone, Chief Executive Officer of LiDCO, said: "HUP is having a transformational impact on our US sales and even with the initial success that we have had so far, year to date recurring revenues are up 95% in local currency versus prior year. We continue to be encouraged by the positive response to our HUP offering. The pipeline of opportunities continues to increase and as we accelerate the speed of conversion of other prospects in this large and growing market, we are confident that we can take further market share."


This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014 ("MAR").


For further information, please contact:


LiDCO Group Plc

Matt Sassone (CEO)

Jill McGregor (CFO)

Tel: +44 (0)20 7749 1500




Tel: +44 (0)20 7600 1658

Geoff Nash / Emily Watts  (Corporate Finance)


Stephen Norcross (Corporate Broking)




Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303





About LiDCO Group Plc (

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre. 


Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay.  LiDCO's computer-based technology, originally developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.


Key Products:


LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring. Version 2 of this software is only available on a new slim widescreen monitor and includes the optional high usage program software in selected markets.


LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness.


LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:


·     early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

·     quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time


The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. 


LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.


*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.


LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 


LiDCO Distribution Network:

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.


LiDCO's headquarters are in London and its shares are traded on AIM.

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t